Survival analysis showed that the expression of METTL3 and IGF2BP3 affected the prognosis of pancreatic cancer patients and that high expression of METTLE/IGF2BP3 can promote the progression of pancreatic cancer (Figures 4K, L). This evidence concerns the gene METTL3 and familial pancreatic carcinoma.